Morgan Stanley Downgrades Simcere Pharmaceutical (SCR) to Equalweight
Tweet
Share
E-mailGet Alerts SCR Hot Sheet
Price: $35.58 --0%
Rating Summary:
2 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
2 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Morgan Stanley downgraded Simcere Pharmaceutical (NYSE: SCR) from Overweight to Equalweight, price target cut from $13 to $9.80.
For an analyst ratings summary and ratings history on Simcere Pharmaceutical click here. For more ratings news on Simcere Pharmaceutical click here.
Shares of Simcere Pharmaceutical closed at $7.76 yesterday.
For an analyst ratings summary and ratings history on Simcere Pharmaceutical click here. For more ratings news on Simcere Pharmaceutical click here.
Shares of Simcere Pharmaceutical closed at $7.76 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Downgrades Accelerant Holdings (ARX) to Sector Perform
- RBC Capital Downgrades CareTrust REIT (CTRE) to Sector Perform
- HSBC Downgrades Cisco (CSCO) to Hold
Create E-mail Alert Related Categories
DowngradesRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
